person · Reporting owner
MAZELSKY JONATHAN JAY
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DENTSPLY SIRONA Inc.XRAY · Entity 4448 | Director | September 30, 2026 | October 03, 2026 |
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Director · President and CEO | February 26, 2026 | March 02, 2026 |
| INSULET CORPPODD · Entity 3516 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DENTSPLY SIRONA Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock (Directors' Deferred Compensation) DDCSEC Table II · derivative / convertible security | Direct | 23,345.1175 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 3,323.4332 · Balance 23,345.1175 F1: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director. F2: Comprised of phantom stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock following the reporting person's termination of service as a director.
F2: Comprised of phantom stock.
IDEXX LABORATORIES INC /DE
Report date February 26, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 83,803.302 |
Ending reported balance
After 2026-02-27 transaction · row 15
15 source rows · reconciled sequenceRow 1 · 2026-02-26 · Exercise / conversion · Acquired 23,326 · Balance 106,932.302 Row 2 · 2026-02-26 · Sale · Disposed 1,281 · Balance 105,651.302 F1: Represents the weighted average price of the shares sold ranging from a low of $650.00 to a high of $650.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 3 · 2026-02-26 · Sale · Disposed 1,095 · Balance 104,556.302 F2: Represents the weighted average price of the shares sold ranging from a low of $651.06 to a high of $651.85 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 4 · 2026-02-26 · Sale · Disposed 1,669 · Balance 102,887.302 F3: Represents the weighted average price of the shares sold ranging from a low of $652.105 to a high of $653.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 5 · 2026-02-26 · Sale · Disposed 1,171 · Balance 101,716.302 F4: Represents the weighted average price of the shares sold ranging from a low of $653.19 to a high of $654.155 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 6 · 2026-02-26 · Sale · Disposed 1,111 · Balance 100,605.302 F5: Represents the weighted average price of the shares sold ranging from a low of $654.24 to a high of $655.2175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 7 · 2026-02-26 · Sale · Disposed 1,488 · Balance 99,117.302 F6: Represents the weighted average price of the shares sold ranging from a low of $655.275 to a high of $656.205 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 8 · 2026-02-26 · Sale · Disposed 1,343 · Balance 97,774.302 F7: Represents the weighted average price of the shares sold ranging from a low of $656.28 to a high of $657.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 9 · 2026-02-26 · Sale · Disposed 2,860 · Balance 94,914.302 F8: Represents the weighted average price of the shares sold ranging from a low of $657.305 to a high of $658.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 10 · 2026-02-26 · Sale · Disposed 3,660 · Balance 91,254.302 F9: Represents the weighted average price of the shares sold ranging from a low of $658.30 to a high of $659.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 11 · 2026-02-26 · Sale · Disposed 2,859 · Balance 88,395.302 F10: Represents the weighted average price of the shares sold ranging from a low of $659.31 to a high of $660.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 12 · 2026-02-26 · Sale · Disposed 1,200 · Balance 87,195.302 F11: Represents the weighted average price of the shares sold ranging from a low of $660.59 to a high of $661.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 13 · 2026-02-26 · Sale · Disposed 1,000 · Balance 86,195.302 F12: Represents the weighted average price of the shares sold ranging from a low of $661.65 to a high of $662.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 14 · 2026-02-26 · Sale · Disposed 2,589 · Balance 83,606.302 F13: Represents the weighted average price of the shares sold ranging from a low of $662.72 to a high of $663.505 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 15 · 2026-02-27 · Exercise / conversion · Acquired 197 · Balance 83,803.302 |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $141.60 · Expires 2027-02-13 | Direct | 0 |
Reported balance
After 2026-02-26 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-02-26 · Exercise / conversion · Disposed 23,326 · Balance 0 F14: Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning February 14, 2018. |
| Incentive Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $505.53 · Expires 2032-02-13 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-02-27 · Exercise / conversion · Disposed 197 · Balance 0 F15: Grant of option to buy shares of Issuer common stock that vested on February 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average price of the shares sold ranging from a low of $650.00 to a high of $650.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F2: Represents the weighted average price of the shares sold ranging from a low of $651.06 to a high of $651.85 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F3: Represents the weighted average price of the shares sold ranging from a low of $652.105 to a high of $653.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F4: Represents the weighted average price of the shares sold ranging from a low of $653.19 to a high of $654.155 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F5: Represents the weighted average price of the shares sold ranging from a low of $654.24 to a high of $655.2175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F6: Represents the weighted average price of the shares sold ranging from a low of $655.275 to a high of $656.205 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F7: Represents the weighted average price of the shares sold ranging from a low of $656.28 to a high of $657.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F8: Represents the weighted average price of the shares sold ranging from a low of $657.305 to a high of $658.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F9: Represents the weighted average price of the shares sold ranging from a low of $658.30 to a high of $659.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F10: Represents the weighted average price of the shares sold ranging from a low of $659.31 to a high of $660.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F11: Represents the weighted average price of the shares sold ranging from a low of $660.59 to a high of $661.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F12: Represents the weighted average price of the shares sold ranging from a low of $661.65 to a high of $662.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F13: Represents the weighted average price of the shares sold ranging from a low of $662.72 to a high of $663.505 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F14: Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning February 14, 2018.
F15: Grant of option to buy shares of Issuer common stock that vested on February 14, 2026.
INSULET CORP
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,496 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 141 · Balance 1,496 F1: These are deferred common stock units ("Deferred Units") received in lieu of cash compensation pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors. The deferred common stock units will be converted into shares of Company common stock on a one-for-one basis upon distribution, with the value of any fractional shares paid in cash. Distribution of shares of common stock occurs, at the election of the director, either in a lump sum or in substantially equal annual installments pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: These are deferred common stock units ("Deferred Units") received in lieu of cash compensation pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors. The deferred common stock units will be converted into shares of Company common stock on a one-for-one basis upon distribution, with the value of any fractional shares paid in cash. Distribution of shares of common stock occurs, at the election of the director, either in a lump sum or in substantially equal annual installments pursuant to the Company's Deferred Compensation Plan for Non-Employee Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 14, 2022 Filed Nov 16, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 18,998 | $62.00 | $1,177,876.00 |
DisclosureSEC source: 0001567619-22-020466 · doc1.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,304.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 24,002 | Not disclosed Strike: $52.00 | Not disclosed |
DisclosureSEC source: 0001567619-22-019388 · doc1.xml · derivative · entry 9 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,002 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · price: Not applicable. F9 · derivative.exercise_date: Grant of option to buy 24,501 shares of Issuer common stock that became exercisable in five annual installments beginning December 5, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 392 | $385.01 | $150,924.78 |
DisclosureSEC source: 0001567619-22-019388 · doc1.xml · nonDerivative · entry 8 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,306.6426 F8 · price: Represents the weighted average price of the shares sold ranging from a low of $384.98 to a high of $385.16 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,018 | $384.47 | $1,160,315.67 |
DisclosureSEC source: 0001567619-22-019388 · doc1.xml · nonDerivative · entry 7 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,698.6426 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $383.97 to a high of $384.935 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,716 | $383.29 | $1,041,005.86 |
DisclosureSEC source: 0001567619-22-019388 · doc1.xml · nonDerivative · entry 6 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,716.6426 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $382.95 to a high of $383.95 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,704 | $382.81 | $1,417,912.31 |
DisclosureSEC source: 0001567619-22-019388 · doc1.xml · nonDerivative · entry 5 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,432.6426 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $381.94 to a high of $382.94 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 500 | $380.85 | $190,426.00 |
DisclosureSEC source: 0001567619-22-019388 · doc1.xml · nonDerivative · entry 4 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,136.6426 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $380.68 to a high of $381.04 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,000 | $379.50 | $758,998.80 |
DisclosureSEC source: 0001567619-22-019388 · doc1.xml · nonDerivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,636.6426 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $379.10 to a high of $380.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 900 | $378.60 | $340,735.59 |
DisclosureSEC source: 0001567619-22-019388 · doc1.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,636.6426 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $377.99 to a high of $378.95 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 24,002 | $52.00 | $1,248,104.00 |
DisclosureSEC source: 0001567619-22-019388 · doc1.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,536.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 17 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2022 Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 385 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-015173 · doc1.xml · derivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,990 Underlying: Common Stock · 385 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. F3 · price: Not applicable. F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 179 | $407.78 | $72,992.62 |
DisclosureSEC source: 0001567619-22-015173 · doc1.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,517.6426 Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 385 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-015173 · doc1.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,696.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 11 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2022. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 706 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001567619-22-011529 · doc1.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 706 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy 706 shares of IDEXX Laboratories, Inc. common stock that vested in one installment on February 14, 2022. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 706 | $141.60 | $99,969.60 |
DisclosureSEC source: 0001567619-22-011529 · doc1.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,300.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 9 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2022. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006475 · doc1.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,585.6426 Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:24 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 690 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004783 · doc1.xml · derivative · entry 15 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,375 Underlying: Common Stock · 690 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F11 · price: Not applicable. F10 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F10 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:24 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 974 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004783 · doc1.xml · derivative · entry 14 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,065 Underlying: Common Stock · 974 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F11 · price: Not applicable. F9 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F9 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:24 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 435 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004783 · doc1.xml · derivative · entry 13 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,039 Underlying: Common Stock · 435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F11 · price: Not applicable. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:24 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 505 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004783 · doc1.xml · derivative · entry 12 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,474 Underlying: Common Stock · 505 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F11 · price: Not applicable. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:24 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 459 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004783 · doc1.xml · derivative · entry 11 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,979 Underlying: Common Stock · 459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2018. F11 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2018. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2018. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:24 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 3,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004783 · doc1.xml · derivative · entry 10 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,438 Underlying: Common Stock · 3,833 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F11 · price: Not applicable. F5 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F5 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:24 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 197 | Not disclosed Strike: $505.53 | Not disclosed |
DisclosureSEC source: 0001567619-22-004783 · doc1.xml · derivative · entry 9 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197 Underlying: Common Stock · 197 shares Expires 2032-02-13 F11 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on the fourth anniversary of the date of grant. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:24 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantPremium Non-Qualified Stock Option (right-to-buy) · Derivative | 12,557 | Not disclosed Strike: $556.08 | Not disclosed |
DisclosureSEC source: 0001567619-22-004783 · doc1.xml · derivative · entry 8 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,557 Underlying: Common Stock · 12,557 shares Expires 2032-02-13 F11 · price: Not applicable. F3 · derivative.exercise_date: Grant of option at a 110% premium to the closing price of Issuer common stock on the NASDAQ Global Select Market on February 14, 2022 to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2023. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:24 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 22,366 | Not disclosed Strike: $505.53 | Not disclosed |
DisclosureSEC source: 0001567619-22-004783 · doc1.xml · derivative · entry 7 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,366 Underlying: Common Stock · 22,366 shares Expires 2032-02-13 F11 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2023. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:24 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 1,423 | $505.53 | $719,369.19 |
DisclosureSEC source: 0001567619-22-004783 · doc1.xml · nonDerivative · entry 6 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,085.6426 Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:24 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 690 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004783 · doc1.xml · nonDerivative · entry 5 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,508.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:24 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 974 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004783 · doc1.xml · nonDerivative · entry 4 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,818.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:24 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 435 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004783 · doc1.xml · nonDerivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,844.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:24 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 505 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004783 · doc1.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,409.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:24 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 459 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-004783 · doc1.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,904.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 19 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2021 and December 31, 2021. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 60 | $675.44 | $40,526.10 |
DisclosureSEC source: 0001567619-21-016001 · doc1.xml · nonDerivative · entry 7 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,426.6426 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $675.29 to a high of $675.47 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 182 | $674.48 | $122,755.71 |
DisclosureSEC source: 0001567619-21-016001 · doc1.xml · nonDerivative · entry 6 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,486.6426 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $674.16 to a high of $674.91 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 488 | $673.69 | $328,760.92 |
DisclosureSEC source: 0001567619-21-016001 · doc1.xml · nonDerivative · entry 5 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,668.6426 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $673.13 to a high of $674.07 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 533 | $672.36 | $358,367.88 |
DisclosureSEC source: 0001567619-21-016001 · doc1.xml · nonDerivative · entry 4 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,156.6426 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $672.08 to a high of $673.02 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 337 | $677.58 | $228,343.04 |
DisclosureSEC source: 0001567619-21-016001 · doc1.xml · nonDerivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,689.6426 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $677.13 to a high of $677.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 983 | $676.38 | $664,886.06 |
DisclosureSEC source: 0001567619-21-016001 · doc1.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,026.6426 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $676.01 to a high of $676.99 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,417 | $675.34 | $2,307,622.77 |
DisclosureSEC source: 0001567619-21-016001 · doc1.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,009.6426 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $675.00 to a high of $675.89 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 385 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-014769 · doc1.xml · derivative · entry 3 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,605 Underlying: Common Stock · 385 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. F3 · price: Not applicable. F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. F2 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning August 5, 2020. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 179 | $705.76 | $126,331.04 |
DisclosureSEC source: 0001567619-21-014769 · doc1.xml · nonDerivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,426.6426 Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 21:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 385 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-014769 · doc1.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,605.6426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 11.6426 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 30, 2021. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-010825 · doc1.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,209 F1 · balance_after: Includes 12 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2021. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,475 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004794 · doc1.xml · derivative · entry 2 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,475 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Not applicable. F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2021. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,475 | $67.85 | $100,078.75 |
DisclosureSEC source: 0001567619-21-004794 · doc1.xml · nonDerivative · entry 1 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 25,000 | Not disclosed Strike: $52.00 | Not disclosed |
DisclosureSEC source: 0001567619-21-004514 · doc1.xml · derivative · entry 9 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,002 Underlying: Common Stock · 25,000 shares Expires 2023-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Not applicable. F6 · derivative.exercise_date: Grant of option to buy 24,501 shares of Issuer common stock that became exercisable in five annual installments beginning December 5, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 100 | $543.14 | $54,314.00 |
DisclosureSEC source: 0001567619-21-004514 · doc1.xml · nonDerivative · entry 8 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,222 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 583 | $542.08 | $316,033.46 |
DisclosureSEC source: 0001567619-21-004514 · doc1.xml · nonDerivative · entry 7 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,322 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $542.08 to a high of $542.09 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 300 | $540.82 | $162,246.78 |
DisclosureSEC source: 0001567619-21-004514 · doc1.xml · nonDerivative · entry 6 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,905 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $540.218 to a high of $541.21 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 500 | $538.83 | $269,415.00 |
DisclosureSEC source: 0001567619-21-004514 · doc1.xml · nonDerivative · entry 5 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,205 Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,069 | $537.84 | $1,650,628.81 |
DisclosureSEC source: 0001567619-21-004514 · doc1.xml · nonDerivative · entry 4 MAZELSKY JONATHAN JAY · CIK 0001556270 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,705 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $537.388 to a high of $538.12 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.